Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds

Bioorg Med Chem Lett. 2004 Feb 23;14(4):941-5. doi: 10.1016/j.bmcl.2003.12.005.

Abstract

Modifications of the alkyl acetic acid portion and the phenyl on pyrrolidine in our lead pyrazole compound 1 afforded the isopropyl compound 9. This compound is a potent CCR5 antagonist showing good in vitro antiviral activity against HIV-1, an excellent selectivity profile, and good oral bioavailability in three animal species. During this investigation, a new method for the preparation of alpha-(pyrrolidin-1-yl)-alpha,alpha-dialkyl acetic acid from a pyrrolidine and alpha-bromo-alpha,alpha-dialkyl acetic acid using silver triflate was discovered. This allowed us to prepare compounds such as 24 and 25 for the first time. A novel Pd-mediated N-dealkylation of alpha-(pyrrolidin-1-yl)acetic acid was also uncovered.

MeSH terms

  • Acetates / chemistry
  • Acetates / pharmacokinetics
  • Administration, Oral
  • Animals
  • Anti-HIV Agents / chemical synthesis*
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacokinetics*
  • Biological Availability
  • CCR5 Receptor Antagonists*
  • Dogs
  • HeLa Cells
  • Humans
  • Macaca mulatta
  • Molecular Structure
  • Monocytes / drug effects
  • Piperidines / chemical synthesis*
  • Piperidines / chemistry
  • Piperidines / pharmacokinetics*
  • Pyrazoles / chemistry
  • Pyrazoles / pharmacokinetics
  • Rats
  • Structure-Activity Relationship

Substances

  • Acetates
  • Anti-HIV Agents
  • CCR5 Receptor Antagonists
  • Piperidines
  • Pyrazoles